Phase II study of Mitonafide in advanced and relapsed colorectal cancer

Background. This study investigated the antitumoral activity in colorectal cancer and toxicity of a 5-day continuous infusion of a new cytostatic agent, Mitonafide, that had previously shown to be neurotoxic when administered as a short daily × 5 days infusion.